Conversely, limited case series suggest that the risk of irAE occurrence with anti-PD-1/PD-L1 therapy in the setting of pre-existing autoimmune disease is comparable to those patients without known history and without identifiable compromise in efficacy (77, 83–85). The gene discussed is CD274; the disease is autoimmune disease.